Table 1.
Clinical Characteristics
| GHD (n = 31) | GHS (n = 25) | AA (n = 20) | |
|---|---|---|---|
|
| |||
| Age (yr) | 47 ± 2 | 47 ± 2 | 46 ± 3 |
| Gender (n) | 13M/18F | 7M/18F | 10M/10F |
| Acromegaly symptom onset (mo) | 81 ± 17 | ||
| Time since acromegaly diagnosis (mo) | 14 ± 7 | ||
| Treatment | |||
| Surgery (n; %) | 28 (90%) | 25 (100%) | 6 (30%) |
| Radiation therapy (n; %) | 24 (77%) | 8 (32%) | 1 (5%) |
| Surgery and radiation (n; %) | 21 (68%) | 8 (32%) | 1 (5%) |
| Anterior pituitary deficiencies | |||
| Adrenal insufficiency (n; %) | 15 (48%) | 3 (12%) | 0 (0%) |
| Hypothyroidism (n; %) | 23 (74%) | 7 (28%) | 0 (0%) |
| Hypogonadism (n; %) | 28 (90%) | 5 (20%) | 3 (15%) |
| Estimated duration of growth hormone deficiency (mo) | 139 ± 20 | ||
| Hormone replacement | |||
| Oral glucocorticoid use (n; %) | 15 (48%) | 3 (12%) | 1 (5%) |
| Inhaled/topical glucocorticoid use (n; %) | 0 (0%) | 2 (8%) | 1 (5%) |
| Thyroid hormone use (n; %) | 23 (74%) | 9 (36%) | 3 (15%) |
| Male testosterone use (n; %) | 10 (77%) | 1 (14%) | 0 (0%) |
| Female estrogen use (n; %) | 11 (61%) | 4 (22%) | 2 (20%) |
| Oral estrogen use (n; %) | 9 (50%) | 3 (17%) | 2 (20%) |
| Transdermal estrogen use (n; %) | 2 (11%) | 1 (6%) | 0 (0%) |
| Tobacco use (n; %) | 4 (13%) | 4 (16%) | 4 (20%) |
| Antihypertensive medication use (n; %) | 6 (19%) | 10 (40%) | 7 (35%) |
| Diabetes medication use (n; %) | 2 (7%) | 1 (4%) | 2 (10%) |
| Free thyroxine (pmol/L) | 14.9 ± 0.7 | 15.9 ± 0.6 | 16.5 ± 0.9 |
| Insulin-like growth factor I (μg/L) | 91.0 ± 8.9 | 137.9 ± 11.4 | 606.5 ± 49.7 |
| Insulin-like growth factor I SDS | −2.0 ± 0.1 | −1.3 ± 0.2 | 5.1 ± 0.8 |
| Fasting growth hormone (nmol/L) | 0.45 ± 0.10 | 1.46 ± 0.34 | |
| Peak growth hormone (μg/L) | 2.93 ± 0.26 | 29.2 ± 4.9 | |
Means ± SEM are presented. GHD = growth hormone deficiency after definitive treatment of acromegaly, GHS = growth hormone sufficiency after definitive treatment of acromegaly, AA = active acromegaly, SDS = standard deviation score.